Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2

被引：0
|
作者：
Kortuem, M. [1 ]
Trudel, S. [2 ]
Cohen, A. D. [3 ]
Richardson, P. G. [4 ]
Lonial, S. [5 ]
Opalinska, J. B. [6 ]
Gupta, I [6 ]
Byrne, J. [6 ]
Zhi, E. [6 ]
Baron, J. [6 ]
Morgan, L. [6 ]
Voorhees, P. M. [7 ]
Popat, R. [8 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin 2, Wurzburg, Germany
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] GlaxoSmithKline, Upper Providence, PA USA
[7] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[8] NHS Fdn Trust, Univ Coll London Hosp, London, England
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
203
引用
收藏
页码：97 / 98
页数：2
相关论文
共 50 条
  • [31] Recovery of ocular events with longer-term follow-up in the DREAMM-2 study of single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim V.
    Jakubowiak, Andrzej
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 53 - 54
  • [32] DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
    Trudel, S.
    Nooka, A.
    Fecteau, D.
    Talekar, M.
    Jewell, R. C.
    Williams, D.
    Evans, J.
    Opalinska, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Characterization of ocular adverse events in patients receiving belantamab mafodotin (belamaf) for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory multiple myeloma (RRMM)
    Trautmann-Grill, K.
    Lonial, S.
    Nooka, A. K.
    Thulasi, P.
    Badros, A. Z.
    Jeng, B. H.
    Callander, N. S.
    Sborov, D.
    Zaugg, B. E.
    Popat, R.
    Degli, Esposti S.
    Baron, J.
    Doherty, A.
    Lewis, E.
    Opalinska, J.
    Paka, P.
    Piontek, T.
    Gupta, I
    Farooq, A., V
    Jakubowiak, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 181 - 181
  • [34] Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3
    Ferron-Brady, Geraldine
    Taylor, Adekemi
    Kaullen, Josh
    Polireddy, Kishore
    McKeown, Astrid
    Sule, Neal
    Struemper, Herbert
    BLOOD, 2023, 142
  • [35] Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
    Lonial, Sagar
    Lee, Hans C.
    Badros, Ashraf
    Trudel, Suzanne
    Nooka, Ajay K.
    Chari, Ajai
    Abdallah, Al-Ola
    Callander, Natalie
    Sborov, Douglas
    Suvannasankha, Attaya
    Weisel, Katja
    Voorhees, Peter M.
    Womersley, Lynsey
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    CANCER, 2021, 127 (22) : 4198 - 4212
  • [36] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Rifkin, Robert M.
    Boyd, Kevin
    Grosicki, Sebastian
    Kim, Kihyun
    Di Raimondo, Francesco
    Dimopoulos, Meletios A.
    Weisel, Katja
    Arnulf, Bertrand
    Hajek, Roman
    Hungria, Vania T. M.
    Spencer, Andrew
    Davis, Randy
    Riccio, Antonio
    Kim, Chanbin
    Wilkes, Jodie
    Rutledge, Ruth
    Talekar, Mala
    Kremer, Brandon E.
    Gupta, Ira
    Mateos, Maria-Victoria
    BLOOD, 2020, 136
  • [37] Exposure-Response (E-R) for Ocular Safety Endpoints for Belantamab Mafodotin (Belamaf), a B-Cell Maturation Antigen (BCMA)-Targeting Agent, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
    Ferron-Brady, Geraldine
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Jewell, Roxanne C.
    BLOOD, 2020, 136
  • [38] DREAMM-2: Assessing efficacy via indirect comparison of single-agent belantamab mafodotin versus selinexor plus dexamethasone combination in anti-CD38 exposed relapsed/refractory multiple myeloma (RRMM).
    Popat, Rakesh
    Suvannasankha, Attaya
    Kapetanakis, Venediktos
    Prawitz, Thibaud
    Sarri, Grammati
    Hughes, Rachel
    Wang, Feng
    Hogea, Cosima
    Ferrante, Shannon Allen
    Willson, Jenny
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)
    Hungria, Vania T. M.
    Weisel, Katja
    Radinoff, Atanas
    Delimpasi, Sosana
    Mikala, Gabor
    Masszi, Tamas
    Li, Jian
    Capra, Marcelo
    Maiolino, Angelo
    Pappa, Vasiliki
    Chraniuk, Dominik
    Osipov, Iurii
    Leleu, Xavier
    Low, Michael
    Kouri, Fotini
    Liboon, John
    Brawley, Chris
    Lewis, Eric
    Tubel, Gabriela
    Li, Mary
    McKeown, Astrid
    Roy-Ghanta, Sumita
    Opalinska, Joanna
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
  • [40] Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf)
    Terpos, Evangelos
    Badros, Ashraf
    Popat, Rakesh
    Rodriguez-Otero, Paula
    Farooq, Asim
    Jeng, Bennie
    Degli Esposti, Simona
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    Palumbo, Antonio
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S421 - S421
12345